Aratana Therapeutics Reports Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aratana Therapeutics (PETX) Tops Q3 EPS by 4c
November 2, 2017 5:06 PM EDTAratana Therapeutics (NASDAQ: PETX) reported Q3 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $6.47 million.
For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.
... More